



Abivax announces the release of its 2023 half-year financial report

September 29, 2023

PARIS, France, September 29, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today the release of its 2023 half-year financial report.

The 2023 half-year financial report is available on the website of the Company (www.abivax.com – “Investors”).

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on X, formerly Twitter, @ABIVAX_.

Contacts

Investor Relations

Abivax

Patrick Malloy

patrick.malloy@abivax.com

+1 847 987 4878

Investors Relations US

LifeSci Advisors

Ligia Vela-Reid

vela-reid@lifesciadvisors.com

+44 7413 825310

Investors Relations France

Seitosei Actifin

Ghislaine Gasparetto

ggasparetto@actifin.fr

+33 6 21 10 49 24

Investor Relations Europe

MC Services AG

Dr. Solveigh Mähler

solveigh.maehler@mc-services.eu

+49 211 529 252 19